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Abstract: Objective: The use of serum ammonia as a novel marker for sepsis compared to lactic acid
levels in intensive care unit (ICU) patients. Design and Interventions: Single arm, prospective clinical
trial to collect arterial blood samples from patients with sepsis. Serial ammonia and lactic acid levels
were sent every six hours for a total of three days. Measurements and results: Compare mean levels
of ammonia and lactic acid in terms of diagnosing sepsis and patient outcome, including length
of stay and mortality. A total of 30 patients were enrolled in the pilot study. On admission, mean
ammonia level was 35.7 µmol/L and lactic acid was 3.06 mmole/L. Ammonia levels checked at the
end of day 2 (ammonia 2-4) and the beginning of day 3 (ammonia 3-1) were higher in patients who
had a microbial culture-proven sepsis (p-values 0.029 and 0.002, respectively) compared to those
without culture-positive sepsis. Ammonia levels did predict a longer hospital stay; ammonia level
of more than 40 µmol/L had a mean hospital stay of 17.6 days vs. patients with normal levels who
had a mean hospital stay of 9.62 days (p-value 0.0082). Conclusion: Elevated ammonia level can be a
novel biomarker for sepsis, comparable to conventional markers. Ammonia levels have a prognostic
utility as elevated levels were associated with longer hospital stay.
Keywords: ammonia; sepsis; microbial cultures; SIRS; bacterial infections; lactic acid
1. Introduction
The Surviving Sepsis Campaign guidelines (SSG) for management of sepsis and septic shock
defined sepsis in 2016 as a life-threatening organ dysfunction caused by a dysregulated host response
to infection. Septic shock is a subset of sepsis with circulatory and cellular/metabolic dysfunction
with a high risk of mortality [1]. The previous definition of sepsis was systemic inflammatory response
syndrome (SIRS) with an identifiable source of infection. At the cellular level, sepsis is a heterogeneous
disease process causing deranged oxygen metabolism. Sepsis is a distributive shock secondary to
microcirculatory heterogeneity, leading to a delivery and consumption mismatch at the cellular levels
secondary to ischemic and cytopathic hypoxia [2].
In 2016, SSG incorporated serum lactic acid as a marker of systemic hypoperfusion [1,3].
However, in recent literature, lactic acid has been scrutinized because of non-anaerobic causes of
hyperlactemia in sepsis [3]. In this study, we aim to determine the significance of elevated serum
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ammonia levels during hospitalization in sepsis and its effects on patient outcomes. We also evaluate
the sensitivity and specificity of ammonia levels in predicting true sepsis as defined above.
Our rationale for studying ammonia primarily stems from the proximity of the urea and Krebs
cycles in mitochondria. We have examined both cycles and hypothesized that: (1) sepsis affects the
nitrosylation of amino acid residues of the electron transport chain, and perivenous glutamine synthase
leads to the hyperammonemia; (2) urease-splitting bacteria are associated with hyperammonemia in
noncirrhotic patients [4].
2. Methods
The ALPS (Ammonia vs. Lactic acid in Predicting Sepsis) pilot study is an investigator-initiated,
single arm trial. The sample size was estimated to be 30 patients for a pilot study. The study was
carried out according to the Code of Ethics of the World Medical Association (Declaration of Helsinki),
and informed consent was obtained. An order set was created in the electronic medical record for timed
ammonia and lactic acid collections. Ammonia and lactic acid levels were designated based on the day
collected and the numbered collection for that day, for example, 1-2 meant the second level drawn on
day 1. The patients were recruited from the emergency department of a Marshall University-affiliated
hospital. We selected potential enrollees as those who were started on a sepsis order set/protocol in
their charts (which entails collection of microbial cultures and starting broad spectrum antibiotics)
on the basis of a presumed diagnosis of sepsis by the emergency physicians. Once admitted to the
hospital, the patients were evaluated by internal medicine residents who confirmed eligibility and
placed the ammonia/lactic acid study order sets. Once the patients were enrolled, the phlebotomist
collected a blood sample every six hours for three days. To ensure accurate test levels, all samples
were transferred on ice to the hospital laboratory. Lactic acid levels (mmole/L) and ammonia levels
(µmol/L) were tested simultaneously on the same blood sample. We considered a normal lactic acid
level as less than 1.2 mmole/L and a normal ammonia level as less than 40 µmol/L. Basic laboratory
testing, including white blood cell counts, procalcitonin levels, and a source of infection, were collected
from the charts. The Acute Physiology and Chronic Health Evaluation II (APACHE II) scores were
calculated to estimate mortality during hospitalization. An unpaired t-test was used to test different
mean levels of ammonia and lactic acid.
Patients were divided into two groups in accordance with the Surviving Sepsis guidelines.
Patients who had SIRS and positive cultures (confirmed sepsis group) were compared to those with
SIRS and negative cultures (non-confirmed group). Staphylococcus epidermidis microbial cultures were
excluded and considered as contaminant. The treating physician chose the broad-spectrum antibiotic
regimen. A subset of infections was considered atypical if they were positive for an extended spectrum
beta-lactamase (ESBL) producing organism or fungal infection.
3. Results
A total of 30 patients had a suspected diagnosis of sepsis on admission and were enrolled in the
study. The mean age of the patients was 58.3 years. A majority (63.3%) of patients were male. A total
of six patients had diagnosis of chronic liver disease and suspected sepsis. Mean ammonia level on
admission was 35.7 µmol/L, and mean lactic acid level on admission was 3.06 mmole/L. Mean white
blood cell count on admission was 17.400 × 103 cells µL. The mean APACHE II score was 20, with a
corresponding mortality of 33%. Mean procalcitonin level on admission was 7.2 ng/dL. A total of nine
patients (30%) died during the study (all deaths were after two days of enrollment), and the remainder
survived to discharge. Table 1 outlines patient characteristics grouped by ammonia level of more than
40 µmol/L. Table 2 outlines the sources of infection in patients enrolled in the study. No difference in
the mean ammonia levels between survivors and non-survivors was found. Nineteen patients (63.3%)
had a positive microbial culture and were regarded as confirmed sepsis. The remaining 11 patients
with a negative microbial culture were ruled out for having sepsis and received an alternate diagnosis.
The following organisms were isolated from those with a positive microbial culture: 13 patients had
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gram-negative bacterial infection (seven klebsiella organisms, three Escherichia coli, and three Serratia
marcescens); the rest had streptococcus pneumonia (three patients) and candida infection (two patients).
Two patients had more than one isolated organism. Out of the 19 patients, five patients (16.7%) grew
ESBL and candida from their cultures, and their antibiotic regimen was changed appropriately to cover
these organisms, i.e., meropenem and caspofungin.
Table 1. Basic characteristics for 30 patients divided by ammonia level of more than 40 µmol/L.
All patients with presumed history of cirrhosis had a hepatitis C infection and had a normal aspartate
aminotransferase (AST) and alanine aminotransferase (ALT) upon enrollment. No significant difference
between groups could be determined due to the small sample size. APACHIE II (Acute Physiology
and Chronic Health Evaluation II) is a score to estimate mortality of hospitalization—integer score
from 0 to 71; a score of 20 carries a 40% mortality during hospitalization. * Cirrhosis is defined by the
presence of clinical and/or laboratory stigmata of chronic liver failure such as but not limited to ascites
or low albumin.
Variable Abnormal Ammonia at Day 2-4(N = 11)
Normal Ammonia at Day 2-4
(N = 19)
Age 58.3 58.5
Female Sex 45% (5) 31% (6)
Ammonia level on admission 35.7 32
White Blood Cell (WBC) 17.4 18.2
Procalcitonin 7.2 7.9
APACHIE II score 20 20
Average AST/ALT on admission 263/244 299/278
History of Liver cirrhosis * 27% (3) 15% (3)
Creatinine 1.85 1.8
Vasopressor requirement 100% (8) 50% (11)
Mechanical ventilator 25% (2) 18% (4)
Death 18% (2) 36.8 (7)
Table 2. Source of infection in patients enrolled in the study.
Source of Infection Percentage % (N)
Pneumonia 50% (15)
Urinary tract infection 13.3 (4)
Infective endocarditis 6.66% (2)
Susceptive sepsis with no source 30% (9)
Ammonia levels checked at the end of day 2 (ammonia level 2-4) were higher in patients who
had a diagnosis of sepsis (47 ± SEM 6.1 vs. 25.75 ± SEM 5.6). Furthermore, the first level check at day
3 (ammonia level 3-1) was consistent with ammonia level 2-4 (47.5 ± SEM 1.69 vs. 33.7 ± SEM 2.5).
This finding was statistically significant, with p-values 0.029 and 0.002, respectively, as illustrated
in Figure 1. This was further supported with the upward trend of serial ammonia levels checked
for patients with sepsis compared to those in whom the diagnosis of sepsis was ruled out and
antibiotic treatment was stopped. Figure 2 are a graphical demonstration that highlight the marked
differentiation between ammonia curves in the two patient groups. We noticed a particular elevation
in ammonia levels 2-4 and 3-1 in patients with positive microbial cultures. This is in concordance with
the statistical significance detected above. The vertical bars represent the standard deviation for each
ammonia value, and no statistical significance was found. The remaining ammonia levels were not
significantly different between the two patient groups.
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Figure 2. Average ammonia level for all patients with (A) negative and (B) positive microbial culture, 
respectively. Mean value at each set point of day for all patient is represented in mathematical closed 
shape (e.g., filled closed circle is representative of ammonia level 1-1). Green dashed line represents 
normal ammonia value. Vertical lines represent standard deviation for each value. Mean ammonia 
level is reported in μmol/L. 
Figure 1. Microbial culture and mean ammonia level 2-4. Microbial cultures include blood, urine,
respiratory secretions. Ammonia level 2-4: ammonia level checked at the end of day 2 of enrollment
or admission to hospital. Mean ammonia level is reported in µmol/L. Values are presented as the
following: mean ± standard error of mean (SEM). Statistically significant value is p < 0.05.
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The mean ammonia level for alive patients was 40.1 µmol/L vs. 35.2 µmol/L for patients who
died during the study; therefore, increased ammonia levels did not predict mortality. However,
ammonia levels did correlate with longer hospital stay, as those with an ammonia level of more than
40 µmol/L had a mean hospital stay of 17.6 days (SEM 3.39 days) vs. patients with normal levels who
had a mean hospital stay of 9.62 days (SEM 1.1 days). This was statically significant, and the unpaired
t-test result had a p-value of 0.0082.
Lactic acid levels were persistently elevated in both patient groups on admission, and no
significant difference was noted. Mean lactic acid levels in blood culture positive patients was
2.908 mmole/L ± 0.4 (SEM) vs. 3.035 mmole/L ± 0.5 (SEM); this was not statically significant with
a p value of 0.8 (Figure 3). We did note that persistent elevation of lactic acid from admission until
day 3 was associated with an ESBL/candidal infection (2.3 ± SEM 0.524 vs. 1.3 ± SEM 0.086 with
p-value 0.0049) (Figure 4).
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We evaluated the sensitivity and specificity of ammonia level 2-4 in association with a positive
culture. Consistent with previous results, ammonia level 2-4 had a very high specificity of
90% (95% CI = 62–99%). This was not statistically significant and is attributed to the small sample size.
The sensitivity of this test was low, with a value of 31%.
4. Discussion
We herein report the results of the ALPS study analyzing the association between elevated
ammonia levels as a specific novel marker for predicting sepsis as per the SSG definition. Our results
show a unique correlation between hyperammonemia measured within 36–48 h from admission and
positive microbial culture. This was statistically significant and ammonia curves—despite having wide
standard deviation bar for each value—were in concordance. This elevation coincides with the timing
of positive microbial culture reporting from the laboratory. Thus, ammonia levels can be helpful in
situations where antibiotics are started before the collection of blood cultures as we assume in these
instances that they are more likely to be negative.
Lactic acid levels were elevated in both patient groups, and it had a poor ability in differentiating
SIRS from sepsis. Our results showed a high specificity for elevated ammonia levels; thus, this test
has the potential benefit of diagnosing patients with sepsis presenting with SIRS. On the other hand,
ammonia level had a low sensitivity and was a poor test to rule out sepsis in patients with SIRS.
We attribute this to the small sample size of patients with identified infection, i.e., the number of true
positives was low. More studies are needed to explore the sensitivity of elevated ammonia levels
in sepsis. Despite low sensitivity, elevated ammonia levels provided an advantage over lactic acid,
which was elevated in both patient groups. This is particularly seen in shock, where hypoperfusion of
tissues—rather than an infectious process—is the main reason for the production of shock.
During the design of the study, we aimed to find an association between ammonia levels and
candida/ESBL infections. However, we were surprised that such infections were instead associated
with elevated lactic acid levels within 36–48 h after admission and not on admission. This could be
explained by the fact that such infections are not routinely covered by the empiric antibiotic regimen
we had selected per our protocol. This means the infection would not have resolved and would have
continue to cause an ongoing sepsis and lactic acid production. Given the low prevalence of such
infections in our study, we question the utility of such results.
Hyperammonemia was associated with longer hospital stays, leading to an increase in morbidity
and financial burden. However, a larger sample size is required to assess whether serum ammonia is a
significant factor in predicting mortality in sepsis.
To the best of our knowledge, there have not been any randomized clinical trials done investigating
the role of ammonia in sepsis. Sepsis affects intrinsic ammonia metabolism in several ways.
These are summarized in Figure 5. The increase in lymphocytic glutaminase activity seen within
12 h from onset can lead to endotoxin-induced hyperammonemia [5]. Ammonia translocates
into the inner mitochondrial membrane via aquaporin-8 mitochondrial channels, which are
down-regulated in lipopolysaccharide-treated animal models, leading to impaired ureagenesis and
causing hyperammonemia [6]. In addition, the rate-limiting step of the urea cycle mediated by carbonyl
phosphate synthase 1 (CPS1) requires Adenosine triphosphate (ATP), which is depleted secondary
to sepsis-induced cytopathic hypoxia [2]. The same step is also regulated by N-acetyl glutamate
synthase (a co-enzyme) that is allosterically regulated by arginine, which is decreased in sepsis [7].
In addition, Gorge et al. concluded that Lipopolysaccharides (LPs)-induced inhibition of glutamate
synthase located in the peri venous hepatic sinusoids that scavenge ammonia with maximal inhibition
within 48 h of the onset of sepsis can lead to hyperammonemia in sepsis [8]. In addition to all the
above mechanisms describing the effect of sepsis on the handling of ammonia, sepsis is considered a
major catabolic state that leads to increased proteolysis [9]. This is associated with amino acid flux
towards the liver [10], which increases the ammonia load [5]. The combination of decreased clearance
and increase load are thought to be the major contributors of increased ammonia in sepsis.
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5. Conclusions
Extrapolated data from animal and human studies have led us to believe that sepsis can lead to
hyperammonemia in the absence of an overt liver dysfunction. Metabolic derangements in protein,
glutamine metabolism, ammonia transport, and ureagenesis are thought to be responsible. In addition,
the timeline of these experiments has revealed that the nadir of these activities fell within 48 h of
J. Clin. Med. 2018, 7, 182 8 of 8
endotoxin induction, which coincides with the transient rise in ammonia level as shown in our study
population. Hence, we conclude that ammonia has the potential of being utilized as a biomarker
of sepsis-induced metabolic dysfunction. Larger and multicenter trials will be needed to verify
our findings.
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